Celltrion's CT-P13 SC Pediatric Crohn's Phase 3 Part 1 Approval Expires, Trial Plan to Be Revised Due to Development Strategy Change
Celltrion disclosed that the Part 1 approval for its global Phase 3 trial of CT-P13 SC subcutaneous formulation in pediatric patients with moderately to severely active Crohn's disease has expired.
The expiration is due to a decision not to submit the Part 2 trial plan following a change in development strategy; under EU CTR, failure to apply for Part 2 within two years of Part 1 approval leads to expiration.
The company plans to finalize the trial design after discussions with regulators, and this issue has no direct short-term impact on funding or shareholder value.
[AI Summary]Celltrion's Part 1 approval expiration for CT-P13 SC pediatric Crohn's trial due to a development strategy change has limited near-term stock impact, but may delay pediatric label expansion, posing a medium-term pipeline valuation overhang.
KOSPI Filing Information
Major Management Matters Related to Investment Decision (Expiration of Approval for Part 1 of European Phase 3 Clinical Trial Plan for CTP13 SC (Remsima Subcutaneous Injection Formulation) Due to Change in Development Strategy (Pediatric Crohn's Disease Patients))